Chia-Yen Dai, M.D. PhD.

Get in Touch

Email: daichiayen@yahoo.com.tw   d820195@kmu.edu.tw

Major Research Interests

1. Molecular epidemiology of hepatitis C virus infection in Taiwan
2. Treatment of patients with acute and chronic hepatitis C
3. Molecular epidemiology of GB virus C/hepatitis G virus infection in Taiwan
4. Molecular epidemiology of TT virus infection in Taiwan
5. Treatment of chronic hepatitis B patients
6. Contrast echo image

Education

Crossed appointments

Hospital Appointments

Principal Clinical and Hospital Service Responsibilities

Major Administrative Responsibilities

Licensure and Certification

Editorial board of scientific journal

1. World Journal of Hepatology since 2013
2. World Journal of Gastrointestinal Pharmacology and Therapeutics, Dataset Papers in Medicine since 2012

Honors and Awards

Publications

1. Dai CY, Chuang WL, Hou NJ, Lee LP, Hsieh MY, Lin ZY, Chen SC, Huang JF, Hsieh MY, Wang LY, Tsai JF, Chang WY, Yu ML. 2006*. Early Mortality in Taiwanese Lamivudine-Treated Patients with Chronic Hepatitis B-Related Decompensation: Evaluation of the Model for End-Stage Liver Disease and Index Scoring Systems as Prognostic Predictors. Clin Ther 28:2081-92. (SCI)
2. Dai CY, Huang JF, Hsieh MY, Lee LP, Ho CK, Chang WY, Yu ML*. 2007 The Role of Gender on Clearance of Hepatitis C Virus: A Different Story in a Hepatitis B and C Endemic Area? Gut 56:737-8 (SCI)
3. Dai CY, Huang JF, Hsieh MY, Lee LP, Hou NJ, Yu ML, Chuang WL*. 2007. Links between triglyceride levels, hepatitis C virus infection and diabetes. Gut Aug 56(8): 1167-1168. (SCI)
4. Dai CY, Chuang WL, Hsieh MY, Lee LP, Huang JF, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Tsai JF, Chang WY, Yu ML*. 2007. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. Antiviral Res. 75(2):146-51
5. Chiou SS, Huang JF, Chang TT, Hsieh MY, Dai CY*, Yu ML, Chang WY, Chuang WL. 2007 SEN and hepatitis virus infections in non-transfused children and pediatric thalassemia patients with multiple transfusions in Taiwan. Digestion 2007 Mar 6;74(3-4):208-214. (Correspondence) (SCI)
6. Dai CY, Chuang WL, Huang JF, Hsieh MY, Yu ML. 2007. Prevention of donor to recipient Transmission of HCV in stem cell transplantation: some issues. Am J Gastroenterol. 102(10):2350-1. (SCI)
7. Hsieh MH, Lee LP, Hsieh MY, Tsai KB, Huang JF, Hou NJ, Chen SC, Lin ZY, Hsieh MY, Wang LY, Dai CY*, Chuang WL, Yu ML. 2007. Hepatic steatosis and fibrosis in chronic hepatitis C in Taiwan. Jpn J Infect Dis. Nov;60(6):377-81. (Correspondence) (SCI)
8. Dai CY, Yu ML, Hsieh MY, Lee LP, Hou NJ, Huang JF, Chen SC, Lin ZY, Hsieh MY, Wang LY, Tsai JF, Chang WY, Chuang WL, 2007. Early response to lamivudine therapy in clinically non-cirrhotic chronic hepatitis B patients with decompensation. Liver Int. Dec;27(10):1364-70. (SCI).
9. Dai CY, Chuang WL, Huang JF, Hsieh MY, Yu ML*. 2008. Possible determinants of rapid virological response suggesting shorter courses of combination therapy for hepatitis C virus genotype 2. Hepatology 48;342 (SCI)
10. Dai CY, Chuang WL, Ho CK, Ou TT, Huang JF, Hsieh MY, Yu ML*. 2008. High Serum Uric Acid as a Novel Risk Factor for Type 2 Diabetes: Response to Dehghan et al. Diabetes Care 31:e67 (SCI)
11. Dai CY, Chuang WL, Ho CK, Hsieh MY, Huang JF, Lee LP, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Tsai JF, Chang WY, Yu ML* 2008. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol 49(1):9-16 (SCI)
12. Dai CY, Chuang WL, Huang JF, Hsieh MY, Yu ML.* 2008. Rapid virological response in hepatitis C virus genotype 1 and early ribavirin exposure. Hepatology 48:692-693 (SCI)
13. Dai CY, Chuang WL, Li-Po Lee, Pan WC, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Yu ML*. 2008. Association between transforming growth factor-beta 1 polymorphism and virologic characteristics of chronic hepatitis C. Transl Res (J Lab Clin Med) 152(4):151-156.
14. Dai CY, Chuang WL, Huang JF, Yu ML*. 2009. Hepatitis B e antigen-negative patients with persistently normal alanine aminotransferase levels and hepatitis B virus DNA > 2000 IU/mL. Hepatology 49:704-5 (SCI)
15. Dai CY, Chuang WL, Ho CK, Yu ML.* 2009. Hepatitis C viremia and serum lipid levels: A clue from an epidemiology study. J Hepatol 50(2):422-423 (SCI).
16. Dai CY, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL*, Yu ML* 2009. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 50(4):712-718 (SCI)
17. Dai CY, Chuang WL, Huang JF, Hsieh MY, Yu ML.* 2009. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: Some concerns. Hepatology 28;49(6):2125 (SCI)
18. Yang JF, Hsieh MY, Hou NJ, Dai CY*, Huang JF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chuang WL, Yu ML. 2009. Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice. Aliment Pharmacol Ther. 29(9):1000-10 (Correspondence) (SCI).
19. Huang CF, Dai CY*, Chuang WL, Ho CK, Wu TC, Hou NJ, Wang CL, Hsieh MY, Huang JF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Tsai JF, Chang WY, Yu ML*. 2009. HBV infection in indigenous children, 20 years after immunization in Taiwan: A community-based study. Prev Med. 48:397-400 (Correspondence) (SCI).
20. Dai CY, Huang CF, Chuang WL, Huang JF, Yu ML* 2009. The substantial role of initial ribavirin dose on the response to peginterferon alpha/ribavirin therapy in patients with genotype 1b chronic hepatitis C. Am J Gastroenterol. 104:2358-9 (SCI)
21. Lin YY, Huang JF, Liu SF, Yu ML, Tsai CH, Yang JF, Lin IL, Dai CY*, Lin ZY, Chen SC, Chang WY, Chuang WL. 2009. Performance characteristics of two real-time PCR assays for quantification of hepatitis B virus DNA. Scand J Infect Dis 9:1-5 (Correspondence) (SCI).
22. Huang JF, Chuang WL, Yu ML, Yu SH, Huang CF, Huang CI, Yeh ML, Hsieh MH, Yang JF, Lin ZY, Chen SC, Dai CY*, Chang WY*. 2009. Hepatitis C virus infection and metabolic syndrome- a community-based study in an endemic area of Taiwan. Kaohsiung J Med Sci. 25:299-305.(Correspondence).
23. Yang JF, Lin YY, Huang JF, Liu SF, Chu PY, Hsieh MY, Lin ZY, Chen SC, Wang LY, Dai CY*, Chuang WL, Yu ML. 2009. Comparison of clinical application of Abbott HBV PCR Kit and VERSANT HBV DNA 3.0 test for measuring serum hepatitis B virus DNA in Taiwanese patients. Kaohsiung J Med Sci. 25:413-22.(Correspondence).
24. Hsieh MH, Ho CK, Hou NJ, Lin WI, Yang JF, Chiu CC, Huang JF, Chang NC, Wang CL, Dai CY*, Chuang WL, Yu ML 2009 Abnormal liver function test results are related to metabolic syndrome and BMI in Taiwanese adults without chronic hepatitis B or C. Int J ObesityInt J Obes (Lond). 33:1309-17 (Correspondence) (SCI)
25. Dai CY, Ho CK, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Yu ML*, Chuang WL* 2010 Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan. J Hepatol 52:160-166 (SCI)
26. Dai CY, Huang JF, Hsieh MY, Chuang WL, Yu ML* 2010 Insulin resistance, viral load and response to peginterferon and ribavirin in patients with chronic hepatitis C virus infection. Gut 59(3):418. (SCI)
27. Dai CY, Chuang WL, Hsieh MY, Huang JF, Lin YY, Chu PY, Hou NY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Yu ML* 2010 Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients. Antiviral Res 85:396-402(SCI)
28. Dai CY, Huang CF, Huang JF, Chuang WL, Yu ML* 2010 HCV genotype 2/3 patients who can receive an abbreviated course of peginterferon/ribavirin: the important role of initial ribavirin doses. Hepatology 51:1861-2 (SCI)
29. Liu SF, Hsieh MH, Hou NJ, Hsieh MY, Huang JF, Dai CY*, Yu ML, Chuang WL. 2010 Hepatitis B virus genotyping by enzyme-linked immunosorbent assay in Taiwan. Hepatol Int 4:601–607 (SCI) (Correspondence)
30. Dai CY. 2010 Treatment Uptake of Patients with Chronic Hepatitis C: Can We Expect and Do More? Dig Dis Sci. 55(12):3300-3 (SCI)
31. Dai CY, Yeh ML, Huang CI, Huang CF, Lin CY, Hou NJ, Hsieh MY, Huang JF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Yu ML, Chuang WL* 2011Transforming Growth Factor-β1 Polymorphism at Position +915 and Chronic Hepatitis C. Gastroenterol J Taiwan 28(1):1-7.
32. Dai CY, Yeh ML, Huang JF, Chuang WL, Yu ML* 2011 Insurance status and treatment candidacy of hepatitis C patients: Taiwanese Patients are luckier. Hepatology 53(4):1399 (SCI)
33. Dai CY, Huang CF, Huang JF, Chuang WL, Yu ML* 2011 Association between virological response and decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in HCV genotype 1: another story. Hepatology. 53:1774-5 (SCI)
34. Dai CY, Yeh ML, Huang CF, Huang JF, Chuang WL, Yu ML* 2011 The outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure treated with antivirals. Hepatology. 54:1108-1109 (SCI)
35. Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chen KC, Chuang WL, Kuo HT, Dai CY*, Yu ML*. 2012 Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J Hepatol 56: 34-40 (Correspondence). (SCI)
36. Huang CF, Yeh ML, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, Hsi E, Juo SH, Dai CY*, Chuang WL, Yu ML. 2012 Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. Antiviral Res. 2012;93:239-44 (Correspondence). (SCI)
37. Hsieh MH, Lin WY, Chien HH, Chien LH, Huang CK, Yang JF, Chang NC, Huang CH, Wang CL, Chuang WL, Yu ML, Dai CY*, Ho CK. 2012 Waist circumference, BMI, and uric acid, blood sugar and triglyceride levels are important risk factors for abnormal liver function tests in Taiwanese. Kaohsiung J Med Sci 28(9):470-6 (Correspondence) (SCI)
38. Wong KM, Yeh ML, Chuang SC, Wang LY, Lin ZY, Chen SC, Tsai JF, Wang SN, Kuo KK, Dai CY*, Yu ML, Lee KT*, Chuang WL 2013 Survival comparison between surgical resection and percutaneous radiofrequency ablation for patients in Barcelona Clinic Liver Cancer early stage hepatocellular carcinoma. Indian J Gastroenterol 2013;32(4):253-7 (Correspondence)
39. Dai CY, Lin CY, Yeh ML, Hsieh MH, Huang CF, Hou NJ, Hsieh MY, Huang JF, Lin ZY, Chen SC, Wang LY, Chang WY, Chen JS*, Yu ML, Chuang WL. 2013 Association between gall bladder stones and chronic hepatitis C: ultrasonographic survey in a hepatitis C and B hyperendemic township in Taiwan. Kaohsiung J Med Sci 29, 430-5 (SCI)
40. Dai CY, Chuang WL, Yu ML* 2013 Pegylated interferon and ribavirin: a therapeutic option in patients who fail to respond to telaprevir-based triple therapy? Hepatology 2013 Oct;58(4):1519-20 (SCI)
41. Huang CF, Yeh ML, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, Hsi E, Juo SH, Dai CY*, Chuang WL, Yu ML. 2013 Clinical utility of host IL-28B genetic variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin. J Gastroenterol Hepatol. 28(9):1515-20. (SCI)
42. Huang CF, Dai CY*, Yeh ML, Huang JF, Huang CI, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chuang WL, Lin YC, Yu ML. 2013 Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients. PLoS One 8(3):e58882 (SCI)
43. Dai CY, Yeh ML, Huang CF, Hou CH, Hsieh MY, Huang JF, Lin IL, Lin ZY, Chen SC, Wang LY, Chuang WL, Yu ML, Tung HD*. 2014 Chronic hepatitis C infection is associated with insulin resistance and lipid profiles. J Gastroenterol Hepatol (in press) (SCI)
44. Dai CY, Chuang WL, Yu ML*. 2014 A 24-week peg-Interferon alpha-2b versus a 12-week peg-Interferon alpha-2b alone or with ribavirin for patients with acute hepatitis C. Hepatology (in press) (SCI)
45. Dai CY, Chuang WL, Yu ML*. 2014 Variants of the inosine triphosphate pyrophosphatase gene and relapse risk following treatment for HCV genotype 2/3. Hepatology (in press) (SCI)